Brazil Hemoglobinopathies Market Size & Outlook, 2022-2030
Brazil hemoglobinopathies market, 2018-2030 (US$M)
Related Markets
Brazil hemoglobinopathies market highlights
- The Brazil hemoglobinopathies market generated a revenue of USD 851.1 million in 2022 and is expected to reach USD 2,196.6 million by 2030.
- The Brazil market is expected to grow at a CAGR of 12.6% from 2023 to 2030.
- In terms of segment, sickle cell disease was the largest revenue generating disease type in 2022.
- Sickle cell disease is the most lucrative disease type segment registering the fastest growth during the forecast period.
Hemoglobinopathies market data book summary
| Market revenue in 2022 | USD 851.1 million |
| Market revenue in 2030 | USD 2,196.6 million |
| Growth rate | 12.6% (CAGR from 2022 to 2030) |
| Largest segment | Sickle cell disease |
| Fastest growing segment | Sickle cell disease |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
| Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, Brazil accounted for 5.4% of the global hemoglobinopathies market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil hemoglobinopathies market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 1,383.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemoglobinopathies Market Scope
Hemoglobinopathies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil hemoglobinopathies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 59.29% in 2022. Horizon Databook has segmented the Brazil hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil has the highest number of people with homozygous sickle trait (HbAS) and sickle disease (HbSS) affecting newborns. According to Malaria Atlas Project, an estimated 100,000 and 3,300 babies are born with HbAS and HbSS each year, respectively. According to Hematology/Oncology and Stem Cell Therapy Journal, in 2019, the prevalence of SCD in Brazilian population ranged from 2% to 10%.
The trihybrid population of Brazil creates ethnicity mixtures. The heterozygotes prevalence for HbS is lower in Southeast and South regions (2%-3%) and is much higher in the Northeast and North regions (6%-10%).
Large patient population coupled with high prevalence is expected to drive the market growth in the region. Brazil is among the few Latin American countries that have mandatory national hemoglobinopathy screening for newborns. Availability of screening programs and linked treatment services is expected to fuel the growth of the market in the country.
Reasons to subscribe to Brazil hemoglobinopathies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Brazil hemoglobinopathies market databook
-
Our clientele includes a mix of hemoglobinopathies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil hemoglobinopathies market , including forecasts for subscribers. This country databook contains high-level insights into Brazil hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Brazil hemoglobinopathies market size, by disease type, 2018-2030 (US$M)
Brazil Hemoglobinopathies Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
